Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-03-03

Clinical Trial Update: RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma [Phase 4]

View source ↗

Summary

Clinical trial update showing Phase 4 study of tunlametinib in NRAS-mutant advanced melanoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tunlametinib (tunlametinib)

Snippet

Sponsor: Fudan University | Conditions: Melanoma Advanced | Phase 4 | Status: RECRUITING